Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
<div><iframe width="480" height="270" src="https://www.youtube.com/embed/BXSlEaOXZdg?feature=oembed" frameborder="0" allowfullscreen="true"></iframe></div>
Amyotrophic lateral sclerosis (ALS) is a paralytic and usually fatal disorder caused by motor-neuron degeneration in the brain and spinal cord. Most cases of ALS are sporadic but about 510% are familial. Mutations in superoxide dismutase 1 (SOD1)<sup>1, 2</sup>, TAR DNA-binding protein (TARDBP, also known as TDP43)<sup>3, 4</sup> and fused in sarcoma (FUS, also known as translocated in liposarcoma (TLS))<sup>5, 6</sup> account for approximately 30% of classic familial ALS. Mutations in several other genes have also been reported as rare causes of ALS or ALS-like syndromes<sup>7, 8, 9, 10, 11, 12, 13, 14, 15</sup>. The causes of the remaining cases of familial ALS and of the vast majority of sporadic ALS are unknown. Despite extensive studies of previously identified ALS-causing genes, the pathogenic mechanism underlying motor-neuron degeneration in ALS remains largely obscure. Dementia, usually of the frontotemporal lobar type, may occur in some ALS cases. It is unclear whether ALS and dementia share common aetiology and pathogenesis in ALS/dementia. Here we show that mutations in UBQLN2, which encodes the ubiquitin-like protein ubiquilin2, cause dominantly inherited, chromosome-X-linked ALS and ALS/dementia. We describe novel ubiquilin2 pathology in the spinal cords of ALS cases and in the brains of ALS/dementia cases with or without UBQLN2 mutations. Ubiquilin2 is a member of the ubiquilin family, which regulates the degradation of ubiquitinated proteins. Functional analysis showed that mutations in UBQLN2 lead to an impairment of protein degradation. Therefore, our findings link abnormalities in ubiquilin2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention.
<div><iframe width="480" height="270" src="https://www.youtube.com/embed/BXSlEaOXZdg?feature=oembed" frameborder="0" allowfullscreen="true"></iframe></div>
Amyotrophic lateral sclerosis (ALS) is a paralytic and usually fatal disorder caused by motor-neuron degeneration in the brain and spinal cord. Most cases of ALS are sporadic but about 510% are familial. Mutations in superoxide dismutase 1 (SOD1)<sup>1, 2</sup>, TAR DNA-binding protein (TARDBP, also known as TDP43)<sup>3, 4</sup> and fused in sarcoma (FUS, also known as translocated in liposarcoma (TLS))<sup>5, 6</sup> account for approximately 30% of classic familial ALS. Mutations in several other genes have also been reported as rare causes of ALS or ALS-like syndromes<sup>7, 8, 9, 10, 11, 12, 13, 14, 15</sup>. The causes of the remaining cases of familial ALS and of the vast majority of sporadic ALS are unknown. Despite extensive studies of previously identified ALS-causing genes, the pathogenic mechanism underlying motor-neuron degeneration in ALS remains largely obscure. Dementia, usually of the frontotemporal lobar type, may occur in some ALS cases. It is unclear whether ALS and dementia share common aetiology and pathogenesis in ALS/dementia. Here we show that mutations in UBQLN2, which encodes the ubiquitin-like protein ubiquilin2, cause dominantly inherited, chromosome-X-linked ALS and ALS/dementia. We describe novel ubiquilin2 pathology in the spinal cords of ALS cases and in the brains of ALS/dementia cases with or without UBQLN2 mutations. Ubiquilin2 is a member of the ubiquilin family, which regulates the degradation of ubiquitinated proteins. Functional analysis showed that mutations in UBQLN2 lead to an impairment of protein degradation. Therefore, our findings link abnormalities in ubiquilin2 to defects in the protein degradation pathway, abnormal protein aggregation and neurodegeneration, indicating a common pathogenic mechanism that can be exploited for therapeutic intervention.